9:00 Arrival refreshments
9:15 Welcome
Paul Breckell, CEO Action on Hearing Loss
Prof. Jonathan Gale, Interim Director University College London (UCL) Ear Institute
Dr. Ralph Holme, Executive Director of Research, Action on Hearing Loss
Session 1: Clinical trials - the learning curve
Chair: Prof. Anne Schilder, evidENT, Ear Institute, University College London, NIHR UCLH BRC Deafness and Hearing Problems theme, UK
9:30 What do patients and clinicians need?
Prof. Douglas Hartley, Nottingham University, UK
9:45 Early Phase Trials in Hearing Disorders; Challenges and Opportunities
Prof. Anne Schilder, evidENT, Ear Institute, University College London, NIHR UCLH BRC Deafness and Hearing Problems theme, UK
10:00 Questions & Answers: the patient view
Hugh Strickland, Corporate Finance Partner at Aaron & Partners Solicitors, UK. Hugh suffers from hereditary hearing loss.
10:20 Morning refreshments and networking
10:40 Atoh1 gene therapy for hearing loss - preclinical and early clinical development
Dr. Richard Colvin, Novartis, USA
11:00 Developing drugs for central hearing loss and tinnitus
Dr Charles Large, Autifony Therapeutics, UK
11:20 Targeted drug delivery to treat hearing loss disorders
Dr Alan C Foster, Otonomy, USA
11:40 Sodium thiosulfate (STS) as otoprotectant to reduce the incidence of cisplatin-induced hearing loss: final results of the siopel 6 trial for standard risk hepatoblastoma (SR-HB)
Dr Penelope R. Brock, Retired Consultant Paediatric Oncologist Great Ormond Street Hospital for Children NHS Foundation Trust, UK
12:00 Lunch and networking
Session 2: Building on success - opportunities and challenges
Chair Dr. Carina Santos, Action on Hearing Loss,UK
1:10 An overview of the mechanisms of hearing loss (and tinnitus) and their potential as therapeutic targets
Prof Jonathan Gale, Interim Director UCL Ear Institute
1:30 Showcase presentations (10 minutes each, without questions)
• Developing stem cell therapies for the treatment of hearing loss
Prof. Marcelo Rivolta, Sheffield University, UK
• Targeted somatic cell neurotrophin gene electrotransfer promotes spiral ganglion neurite outgrowth to enhance cochlear implant performance
Prof. Gary Housley, UNSW Sydney, NSW, Australia
• Development of a unique therapeutic approach for the treatment of noise-induced hearing loss: the allosteric modulation of the mGlu7 receptor
Dr Guillaume Duvey, Pragma Therapeutics, France
• Magnetic Delivery of Therapy to the Cochlea
Dr Benjamin Shapiro, Otomagnetics, USA
• Development of ORC-13661: A Medicine to Prevent Aminoglycoside-Induced ototoxicity
Prof. Edwin W Rubel, University of Washington and Oricula Therapeutics Inc, USA
• A gerbil model to evaluate the effects of drugs on neural correlates of tinnitus and functional hearing
Dr Roland Schaette, UCL-Ear Institute, UK
• Getting the measure of tinnitus
Prof. Deborah Hall, University of Nottingham and NIHR Nottingham Briomedical Rsearch Centre, UK
• Exploring the views and expectations of patients and Professional stakeholders on novel hearing therapies; a qualitative study.
Dr. Matthew Topping, evidENT, Ear Institute, UCL, UK
3:00 Medicines discovery for auditory disease: Right Drug, Right Dose, Right Time, Right Patient
Dr. Rick Cousins, GSK, UK
3:20 Afternoon refreshments
3:40 Panel Discussion
“How to accelerate the development of biological and pharmacological treatments for hearing loss and tinnitus?”
Chair Dr Sohaila Rastan, Independent advisor, UK
Participants:
1.Dr Erik Larsen
Senior Director of Hearing Science and Technology, Decibel Therapeutics, USA
2. Rolf-Jan Rutten
CEO Audion Therapeutics, Netherlands
3. Dr August Wilke
Principal Research Scientist at Chorus, a Division of Eli Lilly and Company , USA
4. Prof. Karen Steel
Professor of Sensory Function at the Wolfson Centre for Age-Related Diseases, King’s College London, UK
5. Prof. Gary Housley
Professor of Physiology and Director of the Translational Neuroscience Facility, School of Medical Sciences, UNSW Sydney, Australia
6. Prof. Deborah Hall
Professor of Hearing Sciences, Faculty of Medicine & Health Sciences, University of Nottingham; Deputy Director of the NIHR Nottingham Biomedical Research Centre, and Hearing Theme, UK
7. Dr Ralph HolmeExecutive Director of Research, Action on Hearing Loss, UK
5:30 Drinks reception and networking